Placeholder Banner

Countdown to BIO 2018 – Blastoff!

June 4, 2018
The historical city of Boston today welcomes the BIO International Convention. Appropriately themed “make history”, the Convention plans to recognize the organization’s 25th year and its many achievements including this annual event which is now the most comprehensive biotech summit anywhere. 

Expected to bring at least 16,500 people together for partnering, education, collaboration and networking, this Convention will let you get done in four days what would have taken a year of scheduling and travel. Speaking of scheduling, BIO One-on-one Partnering™ will be handling 1,400 individual meetings per hour—one of BIO’s busiest partnering meetings ever. We are on course to schedule 44,000 or more meetings during the week. By Wednesday (June 6) we will know if we have achieved our history making attempt at a GUINESS WORLD RECORD® for the “Largest Business Partnering Event.” 

Our countdown series in this space highlighted ways to navigate the Convention, best practices for partnering, the international presence here, the networking opportunities and a view from the past. Now it’s time to put it all together and get to work—and play.

 “Today marks the start of what is sure to be the most inspiring, thought-provoking and actionable industry gathering in biotechnology,” said Jim Greenwood, President and CEO of BIO. “The next four days will provide countless opportunities for enrichment and partnership that will undoubtedly influence the next 25 years of innovation.” 

Let’s revisit some of the highlights of this year’s Convention:

  • The first Henri A. Termeer Biotechnology Visionary Award
    Created in honor of the late Genzyme CEO who was instrumental in transforming Boston into a thriving hub of life science research, development and innovation, this award will be given for the first time to an individual who reflects the leader’s innovative spirit and transformative impact on patients’ lives.
    Announced during Wednesday’s keynote, the award will be given annually. 

Tuesday, June 5

Robin Roberts will be interviewed by BIO President & CEO Jim Greenwood for a discussion about her personal triumphs over breast cancer and a rare blood disorder and her trailblazing career in journalism. 

9:00 a.m. – 10:30 a.m. | Level 3 Ballroom

Wednesday, June 6

BIO President & CEO Jim Greenwood will speak with Rob Reiner about the importance of advocacy for those living with substance abuse and will share his family’s poignant story of overcoming addiction.

9:00 a.m. - 10:30 a.m. l Level 3 Ballroom

A conversation between Jonathan Kraft, President, The Kraft Group & New England Patriots and Bill Sibold, Head, Sanofi Genzyme where they will discuss the business of biotech and sports and focus on such topics as: building teams in business and sports, collaborations, innovation, leadership and culture, social responsibility and Boston as a the City of Champions in both sports and biotech.

12:30 p.m. – 1:30 p.m. | Room 205ABC, Level 2

Tuesday, June 5

A fireside chat with Julie Gerberding, Executive Vice President & Chief Patient Officer at Merck, Ashanthi De Silva, Writer and Rare Disease Editor at The Mighty, Gabriel Maldonado, Executive Director and CEO at TRUEVOLUTION, and Bryce Olson, Global Marketing Director at Intel for a discussion with patient advocates about their paths to diagnosis and how patient advocacy can bring new treatments to patients.

4:15 p.m. – 5:15 p.m. l Room 259B, Level 2   

Wednesday, June 6

A fireside chat with John Maraganore, PhD, CEO at Alnylam Pharmaceuticals. Dr. Maraganore is leading Alnylam as they prepare to launch the first RNAi therapy. Prior to joining Alnylam, he held senior leadership roles at Millennium Pharmaceuticals, Biogen and ZymoGenetics. 

2:00 p.m. – 3:00 p.m. l Room 254A, Level 2  

Thursday, June 7

A fireside chat with Dr. Sue Desmond-Hellman, CEO of the Bill & Melinda Gates Foundation, and Dr. Penny Heaton, CEO of the Bill & Melinda Gates Medical Research Institute, to discuss the roles of both organizations and their strategies to combat infectious diseases globally. 

10:30 a.m. – 11:45 a.m. l Room 253ABC, Level 2   

Monday Highlights Include:

Monday, June 4

A fireside chat with Jay Bradner, MD, President, Novartis Institutes for Biomedical Research (NIBR) for a discussion about how bringing together multiple collaborators can accelerate the drug discovery process. 

1:00 p.m. – 2:00 p.m. l Room 210C, Level 2  

Monday, June 4

A fireside chat with Albert Bourla, COO, of Pfizer, one of the world’s premier innovative biopharmaceutical companies. With almost 25 years at Pfizer, Dr. Bourla has overseen the company’s commercial, strategy, manufacturing and global product development functions. He is also a member of the Company’s Executive Leadership Team.

2:30 p.m. - 3:30 p.m. l Room 210C, Level 2  

Monday, June 4

A fireside chat with Paul Stoffels, Executive Vice President and Chief Scientific Officer at Johnson & Johnson. Dr. Stoffel helps set the company’s agenda and chairs the Johnson & Johnson R&D Management Committee. He joined the company in 2002 with the acquisition of Virco and Tibotec. 

4:00 p.m. – 5:00 p.m. l Room 210C, Level 2  

Monday, June 4

A forward-looking discussion of what’s next for R&D in the global pharmaceutical industry, highlighting noteworthy differences in disease areas of focus and therapeutic targets relevant for companies of all sizes. We will share perspectives on geographic considerations including regions serving as hotbeds of innovative activity and seek to identify the drivers that will shape future areas of value within the pharmaceutical industry.

3:00 p.m. – 4:15 p.m. l Room 205ABC, Level 2